公司动态 - GoodRx宣布临时CEO Scott Wagner延长了对公司的承诺[1] - GoodRx董事会成员Stephen LeSieur和Adam Karol决定辞职[1] - GoodRx董事会主席Trevor Bezdek感谢LeSieur和Karol在公司演变中的角色[2] 公司业务 - GoodRx是美国处方药节省的领先目的地，提供透明和更低价格的药品[2] 投资者关系 - GoodRx鼓励投资者定期查看其投资者关系网站以获取重要信息[3] 前瞻性声明 - GoodRx的新闻稿包含前瞻性声明，涉及公司未来业绩和财务状况等方面[4]

GoodRx Holdings, Inc. (GDRX) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate r ...

Momentum投资 - Momentum投资的核心是跟随股票最近的趋势，无论是向上还是向下[1] - Zacks Momentum Style Score是帮助我们解决哪些指标是最好关注的问题[2] GoodRx Holdings, Inc.分析 - GoodRx Holdings, Inc.目前持有B级的Momentum Style Score[3] - GoodRx Holdings, Inc.目前的Zacks Rank为2 (Buy)[4] - GDRX的股价在过去一周上涨了30.88%，而Zacks Medical Services行业在同一时期持平[5] - GDRX的股价在过去一个月上涨了34.68%，表现优于行业的0.84%[6] - GoodRx Holdings, Inc.过去一个季度股价上涨了39.87%，过去一年上涨了41.05%[7] - GDRX过去20天的平均交易量为1,667,749股[8] - 过去两个月，GDRX的3个盈利预期上调，没有下调，全年的共识预期从$0.31上调至$0.32[9] - 综合考虑所有因素，GDRX是一只2 (Buy)股票，具有B级的Momentum Score[10]

财务表现 - GoodRx Holdings, Inc. 2023年第四季度营收为1.9664亿美元，同比增长6.8% [1] - 每股收益为0.08美元，较去年同期的0.07美元有所增长 [1] - 公司的营收超出了Zacks Consensus Estimate的195.59亿美元，增长幅度为+0.54% [2] 业绩指标 - 月活跃用户为6，略低于分析师平均预期 [5] - 订阅用户为884，低于三位分析师的平均预期987 [5] - 处方交易营收为1.4386亿美元，较六位分析师的平均预期1.385亿美元高出11.2% [6] - 其他营收为0.523亿美元，较六位分析师的平均预期0.515亿美元高出0.5% [6] - 订阅营收为2.315亿美元，低于六位分析师的平均预期2.299亿美元，较去年同期下降5.9% [6] - 制药厂商解决方案营收为2.44亿美元，低于五位分析师的平均预期2.746亿美元，较去年同期下降2% [7] 股价表现 - GoodRx Holdings, Inc.股价在过去一个月内上涨了27.1%，表现优于Zacks S&P 500综合指数的5.2%变化 [8]

Shares of GoodRx Holdings (GDRX 20.40%) rallied by 20.4% on Thursday after the company announced stronger-than-expected quarterly results and a new stock buyback program. A solid quarter In the fourth quarter, GoodRx's revenue grew 7% year over year to $196.6 million, translating to adjusted (non- GAAP) net income of $31.1 million, or $0.08 per share, up from $0.07 per share in the prior-year period. Analysts, on average, were only modeling for earnings of $0.07 per share on slightly lower revenue. GoodRx e ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2023 Earnings Conference Call February 29, 2024 8:00 AM ET Company Participants Whitney Notaro - VP, IR Scott Wagner - Interim CEO Karsten Voermann - CFO Conference Call Participants Stephanie Davis - Barclays Lisa Gill - JPMorgan Charles Rhyee - TD Cowen Michael Cherny - Leerink Jailendra Singh - Truist Jian Li - Evercore ISI Allen Lutz - Bank of America Daniel Grosslight - Citi Craig Hettenbach - Morgan Stanley Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Farg ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.06, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates two times. GoodRx Holdings, Inc., which be ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the fourth quarter and full year 2023, which are consistent with its preliminary results announced on January 10, 2024. Fourth Quarter 2023 Highlights Revenue1 and Adjusted Revenue1,2 of $196.6 million Net loss of $25.9 million; Net loss margin of 13.2% Adjusted Net Income2 of $31.1 million; Adjusted Net ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-K __________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____. Commission File Number: 001-39549 _____________ ...

GoodRx Holdings, Inc. (GDRX) is expected to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on February 29, 2024, might help the stock move higher if these key n ...